1. Home
  2. SNEX vs CYTK Comparison

SNEX vs CYTK Comparison

Compare SNEX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNEX
  • CYTK
  • Stock Information
  • Founded
  • SNEX 1924
  • CYTK 1997
  • Country
  • SNEX United States
  • CYTK United States
  • Employees
  • SNEX N/A
  • CYTK N/A
  • Industry
  • SNEX Investment Bankers/Brokers/Service
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNEX Finance
  • CYTK Health Care
  • Exchange
  • SNEX Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • SNEX 5.1B
  • CYTK 4.6B
  • IPO Year
  • SNEX 1994
  • CYTK 2004
  • Fundamental
  • Price
  • SNEX $102.92
  • CYTK $53.01
  • Analyst Decision
  • SNEX Buy
  • CYTK Buy
  • Analyst Count
  • SNEX 1
  • CYTK 15
  • Target Price
  • SNEX N/A
  • CYTK $75.57
  • AVG Volume (30 Days)
  • SNEX 511.3K
  • CYTK 2.6M
  • Earning Date
  • SNEX 08-05-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • SNEX N/A
  • CYTK N/A
  • EPS Growth
  • SNEX 21.85
  • CYTK N/A
  • EPS
  • SNEX 5.86
  • CYTK N/A
  • Revenue
  • SNEX $129,411,800,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • SNEX N/A
  • CYTK $330.96
  • Revenue Next Year
  • SNEX $22.66
  • CYTK $73.41
  • P/E Ratio
  • SNEX $17.84
  • CYTK N/A
  • Revenue Growth
  • SNEX 53.56
  • CYTK 2635.74
  • 52 Week Low
  • SNEX $50.31
  • CYTK $29.31
  • 52 Week High
  • SNEX $106.98
  • CYTK $59.39
  • Technical
  • Relative Strength Index (RSI)
  • SNEX 64.33
  • CYTK 77.96
  • Support Level
  • SNEX $98.94
  • CYTK $35.22
  • Resistance Level
  • SNEX $106.98
  • CYTK $50.22
  • Average True Range (ATR)
  • SNEX 2.91
  • CYTK 2.29
  • MACD
  • SNEX 0.72
  • CYTK 1.64
  • Stochastic Oscillator
  • SNEX 76.03
  • CYTK 94.73

About SNEX StoneX Group Inc.

StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: